Medicenna Therapeutics Corp.
MDNAF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001807983
No open-market purchases or sales by Medicenna Therapeutics Corp. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Medicenna Therapeutics Corp. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 23
- −2 vs. Q3 2021
- Shares held
- 4.44M
- +1.40M (+45.9%) vs. Q3 2021
- Total value
- $7.42M
- −$1.25M (−14.4%) vs. Q3 2021
- New holders
- 2
- 8 more added
- Sold out
- 4
- 7 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting MDNAF on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 1 | $200.4K |
| Q3 2024 | 1 | $175.0K |
| Q2 2024 | 1 | $145.0K |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 3 | $40.9K |
| Q3 2023 | 26 | $2.45M |
| Q2 2023 | 28 | $4.75M |
| Q1 2023 | 28 | $6.25M |
| Q4 2022 | 28 | $4.75M |
| Q3 2022 | 29 | $9.67M |
| Q2 2022 | 19 | $5.41M |
| Q1 2022 | 20 | $5.47M |
| Q4 2021 | 23 | $7.42M |
| Q3 2021 | 25 | $8.66M |
| Q2 2021 | 26 | $15.4M |
| Q1 2021 | 31 | $22.9M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Medicenna Therapeutics Corp.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| TAP Consulting, LLC | 500 | $1.00K | 0.00% | +500 | New |
| Steward Partners Investment Advisory, LLC | 1,666 | $3.00K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 2,882 | $5.00K | 0.00% | +2,882 | New |
| Tower Research Capital LLC (TRC) | 4,872 | $8.00K | 0.00% | +4,672+2,336.0% | Added |
| Morgan Stanley | 7,340 | $12.0K | 0.00% | −31,265−81.0% | Reduced |
| K.J. Harrison & Partners Inc | 10,000 | $17.0K | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 10,853 | $18.0K | 0.00% | −37,436−77.5% | Reduced |
| McKinley Carter Wealth Services, Inc. | 12,594 | $21.0K | 0.00% | −19,643−60.9% | Reduced |
| Newman Dignan & Sheerar, Inc. | 13,915 | $23.0K | 0.01% | +1,000+7.7% | Added |
| Patriot Financial Group Insurance Agency, LLC | 17,900 | $29.0K | 0.00% | −5,000−21.8% | Reduced |
| Advisor Group Holdings, Inc. | 21,676 | $35.0K | 0.00% | +2,000+10.2% | Added |
| Geode Capital Management, LLC | 27,633 | $45.0K | 0.00% | 00.0% | Unchanged |
| Rathbone Brothers plc | 40,000 | $66.0K | 0.00% | 00.0% | Unchanged |
| Vident Investment Advisory, LLC | 65,878 | $110.0K | 0.00% | +2,998+4.8% | Added |
| Tocqueville Asset Management L.P. | 88,000 | $143.0K | 0.00% | −5,000−5.4% | Reduced |
| Renaissance Technologies LLC | 99,000 | $161.0K | 0.00% | +87,100+731.9% | Added |
| Letko, Brosseau & Associates Inc | 100,000 | $163.0K | 0.00% | 00.0% | Unchanged |
| Sigma Planning Corp | 140,050 | $228.0K | 0.01% | +109,550+359.2% | Added |
| ACT Capital Management, LLC | 152,500 | $249.0K | 0.18% | −197,500−56.4% | Reduced |
| Intact Investment Management Inc. | 359,800 | $752.0K | 0.02% | −25,800−6.7% | Reduced |
| Worth Venture Partners, LLC | 513,089 | $837.0K | 0.42% | +298,059+138.6% | Added |
| Verition Fund Management LLC | 539,051 | $879.0K | 0.01% | 00.0% | Unchanged |
| AIGH Capital Management LLC | 2,214,300 | $3.61M | 1.13% | +1,299,300+142.0% | Added |
| Bank of Montreal | 0 | $0 | 0.00% | −38,053−100.0% | Sold out |
| Davenport & Co LLC | 0 | $0 | 0.00% | −27,750−100.0% | Sold out |
| Deutsche Bank AG | 0 | $0 | 0.00% | −22,900−100.0% | Sold out |
| Gerber Kawasaki Wealth & Investment Management | 0 | $0 | 0.00% | −1−100.0% | Sold out |